67 completed, 6 recruiting, 4 enrolling by invitation, 3 terminated. 24 Phase 1, 21 Phase 3, 3 Phase 2, 3 Phase 4, 1 Not applicable.
Follow Haemophilia A: new trials by email Literature Review of Haemophilia A trials Research Report on Haemophilia A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A Denecimig - Haemophilia A | Phase 3 | Not yet recruiting | Novo Nordisk A/S | 84 | 2026-10-09 | 2026-09-21 |
| Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany No treatment given - Haemophilia A | Enrolling by invitation | Novo Nordisk A/S | 150 | 2026-09-25 | 2026-10-06 | |
| Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®) Clinical Data - Haemophilia A, Factor VIII | Recruiting | Hospices Civils de Lyon | 160 | 2026-01-03 | 2026-07-23 | |
| A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People NNC0442-0344 A - Haemophilia A | Phase 1 | Completed | Novo Nordisk A/S | 80 | 2025-11-18 | 2026-06-17 |
| A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A NNC0442-0344 A - Haemophilia A | Phase 1 | Recruiting | Novo Nordisk A/S | 30 | 2025-10-23 | 2026-09-18 |
| Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients Turoctocog alfa - Congenital Bleeding Disorder, Haemophilia A | Completed | Novo Nordisk A/S | 329 | 2024-11-10 | 2026-06-17 | |
| A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men NNC0442-0344 A, Placebo - Haemophilia A | Phase 1 | Completed | Novo Nordisk A/S | 95 | 2024-09-23 | 2026-04-01 |
| Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors Concizumab - Haemophilia A, Haemophilia B | Enrolling by invitation | Novo Nordisk A/S | 23 | 2024-08-08 | 2026-06-15 | |
| Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. SCT800 prophylaxis and treatment for bleeding events - Haemophilia A | Phase 3 | Recruiting | Sinocelltech Ltd. | 36 | 2024-04-26 | 2026-02-27 |
| Prevalence of Synovitis in Patients With Haemophilia A Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS) - Haemophilia A, Synovitis | Recruiting | University Hospital, Bonn | 300 | 2024-04-15 | 2024-04-16 | |
| A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) NNC0365-3769 (Mim8) PPX - Haemophilia A, Haemophilia A With Inhibitors | Phase 3 | Completed | Novo Nordisk A/S | 61 | 2023-06-26 | 2025-12-08 |
| A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A Mim8 - Haemophilia A, Haemophilia A With Inhibitors | Phase 3 | Active not recruiting | Novo Nordisk A/S | 451 | 2023-02-13 | 2026-09-09 |
| A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge NNC0365-3769 (Mim8) - Haemophilia A | Phase 1 | Completed | Novo Nordisk A/S | 205 | 2023-01-02 | 2025-10-14 |
| An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct Esperoct - Haemophilia A | Completed | Novo Nordisk A/S | 123 | 2022-11-23 | 2026-10-08 | |
| A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors NNC0365-3769 (Mim8) - Haemophilia A, Haemophilia A With Inhibitors | Phase 3 | Completed | Novo Nordisk A/S | 281 | 2021-12-02 | 2025-12-08 |
| Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) turoctocog alfa pegol (N8-GP) - Haemophilia A | Phase 3 | Completed | Novo Nordisk A/S | 36 | 2021-09-27 | 2026-01-06 |
| Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities Turoctocog alfa - Haemophilia A | Completed | Novo Nordisk A/S | 18 | 2021-04-12 | 2023-11-28 | |
| Post-Marketing Surveillance (Use-results Surveillance) With Esperoct® Turoctocog alfa pegol - Haemophilia A | Completed | Novo Nordisk A/S | 23 | 2021-03-31 | 2026-06-15 | |
| Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol Turoctocog alfa pegol - Haemophilia A | Enrolling by invitation | Novo Nordisk A/S | 50 | 2020-12-09 | 2026-10-08 | |
| A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® Turoctocog alfa pegol (N8-GP) - Haemophilia A | Enrolling by invitation | Novo Nordisk A/S | 60 | 2020-10-23 | 2025-12-22 |
Showing 20 of 84. Sign in to see all of them.
Hemophilia A (84) · Hemophilia B (27) · Blood Coagulation Disorders (2) · Coagulation Protein Disorders (2) · Genetic Diseases, Inborn (2) · Hemorrhagic Disorders (2) · Anxiety Disorders (1) · Hematologic Diseases (1) · Hemostatic Disorders (1) · Pain (1) · Synovitis (1)
Blood Coagulation Disorders, Inherited (84) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (84) · Hemic and Lymphatic Diseases (84) · Hematologic Diseases (83) · Blood Coagulation Disorders (82) · Coagulation Protein Disorders (82) · Genetic Diseases, Inborn (82) · Hemorrhagic Disorders (82) · Genetic Diseases, X-Linked (27) · Cardiovascular Diseases (1) · Joint Diseases (1) · Mental Disorders (1) · Musculoskeletal Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1)
recombinant factor VIII N8 (18) · Factor VIII (9) · optivate (4) · F8 protein, human (3) · Factor VII (3) · concizumab (3) · BAY 14-2222 (1) · Blood Specimen Collection (1) · Standard of Care (1) · Therapeutics (1) · Ultrasonography (1) · factor IX Fc fusion protein (1) · factor VIII-Fc fusion protein (1) · protein phosphatase 4 (1) · recombinant FVIII, sugar formulated (1)
Novo Nordisk A/S (64) · Bio Products Laboratory (4) · Swedish Orphan Biovitrum (3) · Bayer (2) · Hospices Civils de Lyon (2) · CSL Behring (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Haemophilia Centre Rhine Main (1) · Hoffmann-La Roche (1) · Octapharma (1) · Recoly N.V. (1) · Sinocelltech Ltd. (1) · University Hospital, Bonn (1)
Germany (38) · Spain (33) · United Kingdom (31) · Italy (29) · France (28) · United States (28) · Japan (23) · Turkey (Türkiye) (18) · Malaysia (17) · Poland (17) · Austria (16) · Israel (15) · Switzerland (15) · Canada (13) · Denmark (13)
Andreas C Strauss, PD Dr. med. (1) · Carmen Escuriola Ettingshausen, MD (1)
PMID 25495795, PMID 25273984, PMID 26679394, PMID 32293786, PMID 15230949, PMID 21443634, PMID 22470921, PMID 23398640, PMID 23647704, PMID 23651313, PMID 23902228, PMID 25641556, PMID 25677761, PMID 25952661, PMID 26058730, PMID 26619194, PMID 26663410, PMID 26931631, PMID 27291066, PMID 27436242, PMID 27577234, PMID 27904904, PMID 28220555, PMID 30013766, PMID 31444162, PMID 31595670, PMID 31618804, PMID 32197139, PMID 32544297, PMID 32940955, PMID 34855619, PMID 35290453, PMID 35460313, PMID 35858373, PMID 36626898, PMID 37180427, PMID 37309365, PMID 37597724, PMID 38734133, PMID 39667975, PMID 40099856, PMID 40323006, PMID 41257207, PMID 42054679, PMID 42469164, PMID 42824064
2008 (3), 2009 (3), 2016 (3), 2015 (2), 2017 (2), 2005 (1), 2014 (1), 2023 (1), 2025 (1)